Processa Pharmaceuticals, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Processa Pharmaceuticals, Inc. (PCSA) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $1.51 thousand as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2025-08-07
- 2025-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.51K.
- 2025-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.10K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3.13K.
- 2024-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $4.61K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-06-30 | $1.51K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.10K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $3.13K 10-K · filed 2025-03-20 |
| 2024-09-30 | $4.61K 10-Q · filed 2024-10-30 |
| 2024-06-30 | $6.51K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $8.82K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $11.88K 10-K · filed 2024-03-29 |
| 2023-09-30 | $14.98K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $18.53K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $22.47K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $26.79K 10-K · filed 2023-03-30 |
| 2022-09-30 | $31.20K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $3.27K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $4.07K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $5.29K 10-K · filed 2022-03-30 |
| 2021-09-30 | $7.02K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $9.19K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $11.79K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $14.81K 10-K · filed 2021-03-25 |
| 2020-09-30 | $16.15K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $19.54K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $23.39K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $27.46K 10-K · filed 2020-03-06 |
| 2019-09-30 | $32.07K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $37.07K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |